Cardiology
Bivalirudin Versus Heparin in Primary PCI for STEMI: Efficacy Across Low and High Bleeding Risk Patients – Insights from the BRIGHT-4 Trial
The BRIGHT-4 trial demonstrates that bivalirudin with prolonged infusion reduces 30-day mortality and major bleeding compared to heparin in STEMI patients undergoing radial primary PCI, benefiting both low and higher bleeding risk groups.
